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This study tested whether a low dose (40% less than the pharmacological dose of 17-𝛽 estradiol) would be as effective as the
pharmacological dose to improve cardiovascular parameters and decrease cardiac oxidative stress. Female Wistar rats (𝑛 =
9/group) were divided in three groups: (1) ovariectomized (Ovx), (2) ovariectomized animals treated for 21 days with low dose
(LE; 0.2mg), and (3) high dose (HE; 0.5mg) 17-𝛽 estradiol subcutaneously. Hemodynamic assessment and spectral analysis for
evaluation of autonomic nervous system regulation were performed. Myocardial superoxide dismutase (SOD) and catalase (CAT)
activities, redox ratio (GSH/GSSG), total radical-trapping antioxidant potential (TRAP), hydrogen peroxide, and superoxide anion
concentrations were measured. HE and LE groups exhibited an improvement in hemodynamic function and heart rate variability.
These changes were associated with an increase in the TRAP, GSH/GSSG, SOD, and CAT. A decrease in hydrogen peroxide and
superoxide anion was also observed in the treated estrogen groups as compared to the Ovx group. Our results indicate that a low
dose of estrogen is just as effective as a high dose into promoting cardiovascular function and reducing oxidative stress, thereby
supporting the approach of using low dose of estrogen in clinical settings to minimize the risks associated with estrogen therapy.
1. Introduction
The risk of cardiovascular disease (CVD) increases dramat-
ically in the postmenopausal women as compared to the
premenopausal women. Estrogen helps to protect women
against CVD during the childbearing years and, after
menopause, the CVD can be prevented or at least reduced
by estrogen therapy [1–3]. It has been demonstrated that
estrogen therapy can reduce many risk factors, improving
lipid profile and glucose metabolism [1].
The increased risk of CVD inmenopause is also accompa-
nied by oxidative stress, a condition when there is an increase
in reactive oxygen species (ROS) levels which may cause
oxidative damage to cells [4]. On the other hand, cells have
mechanisms to protect from ROS mediated toxicity. Glu-
tathione (GSH) is the major nonenzymatic antioxidant and
participates in many cellular reactions of ROS scavenging. In
such reactions, GSH is oxidized to form glutathione disulfide
(GSSG). An increase in the redox ratio which is represented
by GSH/GSSG is indicative of reduced oxidative stress [5].
An impairment in redox balance plays an important role in
the reduced nitric oxide bioavailability which may ultimately
affect the sympathovagal balance (SVB) [6, 7]. Moreover,
some studies have reported a link between menopause and
SVB impairment [8, 9] suggesting a role of estrogen in the
autonomic nervous control of the cardiovascular system.
Power spectral analysis of heart rate variability (HRV) is
a noninvasive method to assess SVB [10]. Alterations in HRV,
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which primarily reflect the tonic autonomicmodulation,may
have substantial clinical implications. Low HRV, which has
been shown in postmenopausal women, is associated with
an increased risk of CVD [11]. In addition, some studies
indicate that menopausal women have a sympathovagal
imbalance and that estrogen improves the SVB centrally
and peripherally by decreasing sympathetic and increasing
parasympathetic tone [12].
Estrogen therapy improveswomen’s quality of life [13] and
is widely used for controlling typical menopausal symptoms
such as vaginal atrophy, hot flushes, osteoporosis, and sleep
disturbances [14]. However, at standard pharmacological
doses, several adverse effects, including higher risk of breast
cancer, stroke, and venous thromboembolism, outweigh the
benefits of estrogen therapy [15].
As cardiovascular diseases are highly prevalent after
menopause [16] and estrogen is the most commonly used
treatment to reduce menopause symptoms [13], the need to
find a safer estrogen dose to control menopause related dis-
comforts has been recommended. Indeed, studies evaluating
different regimens of hormone therapy have demonstrated
that a low dose of estrogen is associated with a significant
decrease in mammographic density [17]. According to Mer-
curo et al. [18], low doses of estrogen are just as effective
as conventional doses to improve the lipid profile and the
endothelial function. Moreover, a low dose of estrogen has
demonstrated to be effective for the alleviation of climacteric
symptoms [19] and it has good tolerability associated with a
low incidence of the most common side effects [20].
There have been no studies to date that have tested the
effects of low dose of estrogen on oxidative stress and its asso-
ciation with the cardiac autonomic control in ovariectomized
rats. Thus, the aim of this study was to test whether the
treatment with a low dose of 17-𝛽 estradiol to ovariectomized
rats could be as effective as a pharmacological dose to reduce
the cardiac oxidative stress and improve the SVB.
2. Methods
2.1. Drugs and Reagents. Ketamine hydrochloride was pur-
chased from Ko¨nig Lab S.A., SP, Brazil, and xylazine, from
Virbac do Brazil I.P., SP, Brazil. 17-𝛽 estradiol and all other
drugs/reagents were purchased from Sigma Chemical Co., St.
Louis.
2.2. Animals and Groups. In total, 27 female Wistar rats
(body weight 200–230 g) from the animal care of the Federal
University of Rio Grande do Sul, Brazil, were kept at 20–22∘C
in a 12 : 12 h dark/light cycle. They were subjected to bilateral
ovariectomy under ketamine hydrochloride (80mg/kg i.p.)
and xylazine (16mg/kg i.p.) anesthesia. After one week
following ovariectomy, each ovariectomized animal received
subcutaneously (under ketamine and xylazine anesthesia)
silastic capsules either filledwith 17-𝛽 estradiol diluted in sun-
flower oil (treated groups) or only sunflower oil as a vehicle
(ovariectomized control group). Rats were divided into three
experimental groups (𝑛 = 9, per group): (1) ovariectomized
(Ovx) receiving only sunflower oil, (2) animals treated with
40% of the pharmacological (LE; 0.2mg/pellet for 21 days)
dose of estradiol, and (3) animals treated with a pharmaco-
logical (HE; 0.5mg/pellet for 21 days) dose of estradiol [21].
All animals had access to water and regular rodent chow ad
libitum. All procedures were approved by the Institutional
Animal Care Ethics Committee and the experiments were
conducted in accordance with the Guide for the Care and
Use of Laboratory Animals (US Department of Health and
Human Services, NIH publication number 86-23).
2.3. Hemodynamic Measurements. Under anesthesia (keta-
mine 80mg/kg, i.p.; xylazine 16mg/kg, i.p.), the left carotid
artery was cannulated with a PE 50 catheter connected to a
strain gauge transducer (Narco Biosystem Pulse Transducer
RP-155, Houston, TX, USA) linked to a pressure ampli-
fier (HP 8805C, Hewlett Packard). Pressure readings were
recorded on a microcomputer equipped with an analog-
to-digital conversion board (WinDaq, 2 kHz sampling fre-
quency; DataQ Instruments, Inc., Akron, OH). The catheter
was advanced into the left ventricle (LV) to record the left ven-
tricular systolic pressure (LVSP, mmHg), the left ventricular
end-diastolic pressure (LVEDP, mmHg), +dP/dt (mmHg/s),
−dP/dt (mmHg/s), and heart rate (HR). After hemodynamic
measurements, animals were sacrificed by decapitation for
heart and blood collection.
2.4. Autonomic Evaluation. After detecting the pulse inter-
vals, the heart rate was automatically calculated on a beat-
to-beat basis as the time interval between two consecutive
systolic peaks or pulse interval (PI). All detection was care-
fully checked to avoid erroneous or missed beats. Sequences
of 150–160 beats were randomly chosen and if there was an
inconsistent pattern, it was discarded and a new random
selection was performed. Frequency domain analysis of HRV
was performed with an autoregressive algorithm [22] on
the PI interval sequences (tachograms) and on respective
systolic sequences (cystograms). The power spectral density
was calculated for each time series. In this study, two spectral
components were considered: low frequency (LF), from 0.10
to 1.00Hz and high frequency (HF), from 1.00 to 5.00Hz.The
spectral components were expressed in absolute (abs) and
normalized units (nu). Normalization consisted of dividing
the power of a given spectral component by the total power,
then multiplying the ratio by 100 [23]. All recordings were
performed in a sound attenuated room. The ratio of LF/HF,
as an index of SVB, was also calculated.
2.5. Plasma Hormone Concentration. Plasma estradiol was
measured by electrochemiluminescence (Roche Diagnostics)
at the Weinmann Clinical Analysis Laboratory. Briefly, this
test employs the principle of competitive assay using a
polyclonal antibody against the 17-𝛽 estradiol.
2.6. Hydrogen Peroxide Concentration. The assay was based
on the horseradish peroxidase- (HRPO-) mediated oxidation




, leading to the formation of a com-
poundmeasureable at 610 nm.Heart slices were incubated for
30min at 37∘C in 10mmol/L phosphate buffer consisting of
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140mmol/L NaCl and 5mmol/L dextrose. The supernatants
were transferred to tubes with 0.28mmol/L phenol red and
8.5U/mL HRPO. After 5min incubation, 1mol/L NaOH was






2.7. Determination of Superoxide Anion Concentration.
Superoxide anion concentration was determined in heart
mitochondrial samples isolated by centrifugations. It was
based on the spectrophotometric measurement of the
epinephrine oxidation reaction in which superoxide anion
is a reactant, leading to the formation of a compound meas-
ureable at 480 nm. The results were expressed in mmol/mg
protein [25].
2.8. Preparation of Heart Homogenates for Analysis of Antiox-
idants. Hearts were homogenized in an ultra-Turrax blender
using 1 g of tissue for 5mL of 150mmol/L potassium chlo-
ride added to 20mmol/L phosphate buffer, pH 7.4. The
homogenates were centrifuged at 1000 g for 20min at −2∘C
as described elsewhere [26].
2.9. TRAP. Total antioxidant capacity (TRAP) was mea-
sured by chemiluminescence using 2,2󸀠-azo-bis(2-amidi-
nopropane) (ABAP, a source of alkyl peroxyl free radicals)
and luminol. A mixture consisting of 20mmol/L ABAP,
40 𝜇mol/L luminol, and 50mmol/L phosphate buffer (pH
7.4) was incubated to achieve a steady-state luminescence
from the free radical-mediated luminol oxidation. A calibra-
tion curve was obtained by using different concentrations
(between 0.2 and 1 𝜇mol/L) of Trolox (hydrosoluble form
of vitamin E). Luminescence was measured in a liquid
scintillation counter using the out-of-coincidence mode and
the results were expressed in units of Trolox/mg protein [27].
2.10. Determination of Total and Oxidized Glutathione Con-
centration. To determine oxidized (GSSG) and total glu-
tathione concentration, tissue was homogenized in 2mol/L
perchloric acid and centrifuged at 1000 g for 10min and
2mol/L potassium hydroxide was added to the supernatant.
The reaction medium contained 100mmol/L phosphate
buffer (pH 7.2), 2mmol/L NADPH, 0.2U/mL glutathione
reductase, and 70 𝜇mol/L 5,5󸀠 dithiobis (2-nitrobenzoic acid).
To determine oxidized glutathione, the supernatant was neu-
tralized with 2mol/L potassium hydroxide and inhibited by
the addition of 5𝜇mol/L N-ethylmaleimide and absorbance
was read at 420 nm [28]. Reduced glutathione (GSH) values
were determined from the total andGSSG concentration.The
redox status was represented by the GSH/GSSG ratio.
2.11. Determination of Antioxidant Enzyme Activities. Super-
oxide dismutase activity was expressed as units per milligram
of protein and is based on the inhibition of superoxide
radical reaction with pyrogallol [29]. Catalase activity was
determined in heart homogenates by following the decrease
in absorption of hydrogen peroxide. It was expressed as
pmol/mg protein [30]. Protein was measured in heart
Table 1: Morphometrics data.
Ovx (𝑁 = 9) LE (𝑁 = 9) HE (𝑁 = 9)
Uterine weight (g) 0.15 ± 0.01 0.63 ± 0.02∗ 0.89 ± 0.13∗†
Body weight (g) 234 ± 11 209 ± 9∗ 210 ± 7∗
Data are mean ± SD. Ovx: ovariectomized group; HE: high dose estrogen-
treated group; LE: low dose estrogen-treated group. ∗𝑃 < 0.05 versus Ovx;
†
𝑃 < 0.05 versus LE.
Table 2: Left ventricular hemodynamic parameters.
Ovx (𝑁 = 5) LE (𝑁 = 5) HE (𝑁 = 5)
LVEDP (mmHg) 12.17 ± 4.54 5.10 ± 1.98∗ 7.95 ± 2.21∗
LVSP (mmHg) 101.71 ± 12.78 120.91 ± 20.71 110.40 ± 7.51
HR (bpm) 212 ± 12.78 221 ± 22.59 183.81 ± 20.83
+dP/dt (mmHg/s) 5809 ± 924 6435 ± 549 5505 ± 450
−dP/dt (mmHg/s) −3946 ± 786 −5262 ± 890 −4098 ± 251
Data are mean ± SD. Ovx: ovariectomized group; HE: high dose estrogen-
treated group; LE: low dose estrogen-treated group. ∗𝑃 < 0.05 versus Ovx.
homogenates, using bovine serum albumin as described by
Lowry et al. [31].
2.12. Statistical Analysis. Data are shown as mean ± standard
deviation. Statistical analyses were performed using one-way
ANOVA followed by Student Newman-Keuls post hoc test.
The Pearson correlation was used to assess the association
among variables. 𝑃 < 0.05 was considered significant.
3. Results
3.1. Ovariectomy and Estradiol Therapy. As expected, the
ovariectomy decreased plasma estrogen concentration and
17-𝛽 estradiol treatment increased its concentration (LE = 587
± 19 pg/L, HE = 1813 ± 37 pg/L versus Ovx = 58 ± 6 pg/L).
This result is in consonance with Paigel et al. [32], who
observed serum estrogen levels in ovariectomized rats similar
to those observed by us. Moreover, in ovary-intact animals,
Paigel et al. [32] found estrogen serum concentration of about
120 pg/L. The 17-𝛽 estradiol treatment also significantly (𝑃 <
0.001) decreased the body weight and increased the uterine
weight (Table 1), confirming the effectiveness of hormonal
treatment.
3.2. Hemodynamic Parameters. The LVEDP, which is a dias-
tolic function, was significantly (𝑃 < 0.05) decreased in
LE (by 60%) and HE (by 35%) groups when compared to
Ovx animals. Moreover, no changes were found in +dP/dt,
a cardiac contractility index, and −dP/dt, a cardiac relaxation
index, LVSP, and HR, among any of the groups (Table 2).
3.3. Autonomic Evaluations. Hfabs, which represents the
parasympathetic drive, and HRV were significantly higher
(𝑃 < 0.05) in both the HE and LE groups as compared to
the Ovx group. LFabs, LFnu, HFnu, and LF/HF ratio did
not show any statistically significant differences with estrogen
treatment (Table 3).
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Table 3: Power spectral analysis.
Ovx (𝑁 = 5) LE (𝑁 = 5) HE (𝑁 = 5)
HRV (ms2) 14.34 ± 3.56 39.98 ± 11.00∗ 69.62 ± 27.32∗
LFabs (ms2) 2.49 ± 1.53 5.03 ± 1.89 8.09 ± 7.04
HFabs (ms2) 9.78 ± 2.84 28.04 ± 9.718∗ 53.35 ± 29.96∗
LFnu 20.22 ± 5.20 16.67 ± 5.12 11.05 ± 3.03
HFnu 79.77 ± 5.14 83.32 ± 5.10 88.95 ± 15.74
LF/HF 0.25 ± 0.07 0.2 ± 0.07 0.12 ± 0.08
Data are mean ± SD. Ovx: ovariectomized group; HE: high dose estrogen-
treated group; LE: low dose estrogen-treated group; HRV: heart rate variabil-
ity; LFabs: absolute low frequency; HFabs: absolute high frequency; LFnu:


























































Figure 1: (a) Hydrogen peroxide concentration in myocardium
(in nmol/g tissue) and (b) superoxide anion concentration in
myocardium (inmmol/mg protein). Data are mean ± SD.𝑁 = 9 per
group. Ovariectomized group = Ovx; ovariectomized group treated
for 21 days with low dose of estrogen = LE; ovariectomized group
treated for 21 dayswith high dose of estrogen=HE. ∗𝑃 < 0.05 versus
Ovx.




concentration (in nmol/g tissue) was significantly decreased
(𝑃 < 0.05) in estrogen groups as compared to the Ovx
group (LE = 0.43 ± 0.10; HE = 0.38 ± 0.14 versus Ovx =
0.83 ± 0.32 (Figure 1(a)). Similarly, the cardiac superoxide
anion concentration (mmol/mg protein) was significantly
(𝑃 < 0.05) decreased in the treated groups (LE = 6.87 ± 3.13;
HE = 2.65 ± 1.37) as compared to the Ovx group (Ovx =
12.22 ± 3.90) (Figure 1(b)).
3.5. TRAP, Glutathione Concentration, and the Redox Ratio.
Total antioxidant capacitywas significantly higher in estrogen
treated groups as compared to the Ovx group. Moreover, a
strong positive correlation between TRAP and HRV (𝑟 =
0.8922; 𝑃 < 0.01) was also observed. GSSG levels decreased














































Figure 2: (a) Superoxide dismutase activity (U/mg protein) and (b)
catalase activity (pmol/mg protein). Data are mean ± SD.𝑁 = 9 per
group. Ovariectomized group = Ovx; ovariectomized group treated
for 21 days with low dose of estrogen = LE; ovariectomized group
treated for 21 dayswith high dose of estrogen=HE. ∗𝑃 < 0.05 versus
Ovx.
(GSH/GSSG) ratio, which is an index of oxidative stress, and
GSHwere significantly (𝑃 < 0.05) higher in both the estrogen
treated groups when compared to the Ovx group (Table 4).
3.6. Antioxidant Enzyme Activities. SOD and CAT activities
were significantly higher in estrogen treated groups (SOD in
U/mg protein: LE = 33.65 ± 5.54; HE = 32.10 ± 6.80; CAT in
pmol/mg protein: 12.5 ± 2.0; 12.8 ± 2.9) as compared to the
Ovx group (SOD: 22.24±3.00; CAT: 8.9±1.4), and there was
no difference between HE and LE groups (Figures 2(a) and
2(b)).
4. Discussion
The present study showed for the first time that a low dose
of estrogen is just as effective as a high dose to improve the
antioxidant reserve and reduces cardiac oxidative stress. This
was associated with a lower LVEDP and higher HRV, which
signifies reduced cardiovascular risk.
In this study, we reported a significant decrease in LVEDP
in both estrogen-treated groups. This result is in agreement
with a study from Bhuiyan et al. [33] who demonstrated
similar values of LVEDP in ovariectomized rats. Moreover,
we did not observe significant differences in +dP/dt, an
index of myocardial contractility, or −dP/dt, an index of
myocardial relaxation, neither in LVSP andHR. Furthermore,
our study also is in consonance with Nekooeian and Pang
[34] who documented a decrease in LVEDP in rats treated
with a pharmacological dose of estrogen. This result suggests
a reduction in afterload with maintained systolic function.
Indeed, in another study we observed that estrogen therapy
induces an increase in aortic nitric oxide bioavailability,
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Table 4: Myocardial nonenzymatic antioxidant defenses.
Ovx (𝑁 = 9) LE (𝑁 = 9) HE (𝑁 = 9)
TRAP (units of Trolox/mg protein) 25.50 ± 7.96 57.60 ± 24.13∗ 53.55 ± 16.15∗
Total GSH (nmol/mg protein) 0.18 ± 0.08 0.32 ± 0.06∗ 0.28 ± 0.14∗
GSSG (nmol/mg protein) 0.026 ± 0.008 0.022 ± 0.005 0.014 ± 0.005∗
GSH/GSSG 5.98 ± 2.45 13.57 ± 2.23∗ 19.55 ± 9.03∗
Data are mean ± SD. Ovx: ovariectomized group; HE: high dose estrogen-treated group; LE: low dose estrogen-treated group. ∗𝑃 < 0.05 versus Ovx.
resulting in an increase in vasodilation and blood pressure
reduction [7]. Estradiol has been reported to play a role
in mediating a reduction in blood pressure in hypertensive
female animalmodels [7, 35, 36]. Moreover, since nitric oxide
is reported to increase diastolic distensibility [37], estrogen
treatment could prevent the increase of LVEDP by increasing
nitric oxide synthase activity in the heart as reported by
others [38].
We did not find changes in LFa, LFnu, HFnu, and LF/HF
ratio in the two treated groups. These results are consistent
with Schuchert et al. [39] who have also demonstrated
no changes in these parameters after estrogen treatment.
On the other hand, HFabs, an important index of cardiac
parasympatheticmodulation [23], was significantly improved
after estrogen treatment representing reduced cardiovascular
risk [40]. HRV was also increased in the estrogen treated
groups. This result is in agreement with Liu et al. [41] who
have reported that estrogen therapy is able to improve cardiac
autonomic control. Although no changes were found in HR,
our results demonstrated that there was a significant increase
in HRV after estrogen treatment. This result highlights the
effectiveness of estrogen, even in a low dose, to increase
HRV and potentially lower the risk factors for cardiovascular
complications [42]. More importantly, in our current study,
we also found a positive correlation between HRV and TRAP
(𝑟 = 0.8922; 𝑃 < 0.01), suggesting that an increase in the
antioxidant capacity might contribute to the improvement
in cardiac autonomic control. This association supports the
hypothesis that estrogen administration increases nonen-
zymatic antioxidants, which improves cardiac autonomic
control and reduces oxidative stress. According to Semen et
al. [43], a decrease in oxidative stress results in an improved
HRV. It has also been reported that estrogen therapy leads
to an increase in total serum antioxidant capacity resulting
in an improvement in the antioxidant status in women [44].
Accordingly, in the treated groups, we have observed an
increase in TRAP that represents an index of nonenzymatic
antioxidants, especially the hydrosoluble ones. One possible
explanation to this preservation in the nonenzymatic antiox-
idants could be the enhanced antioxidant enzyme activity.
In fact, SOD and CAT activities were significantly higher
after estrogen treatment. These results are in agreement with
others who have reported that estradiol has antioxidant prop-
erties whereby it increases CAT [45] and SOD activities and
decreases NADPH oxidase enzyme activity and superoxide
production [7, 45–47]. In the present study a significant
decrease in cardiac concentrations of superoxide anion and
hydrogen peroxide in animals treated with estrogen was also
documented. These results are in consonance with a study of
Lam et al. [48] who demonstrated a significant decrease in
superoxide anion production in aortas from ovariectomized
rats treated with estrogen. According to our results, the low
dose was also able to decrease these ROS concentrations.
Additionally, it is widely recognized that estrogen exhibits
protective antioxidant effects through the phenolic hydroxyl
group of 17-𝛽 estradiol that can act as a ROS scavenger [49].
Our findings do suggest that estrogen, even in a low dose, is
able to improve the antioxidant defenses and decrease ROS
concentrations.
Indeed, GSH/GSSG ratio was significantly increased and
GSSG was decreased in our treated groups. These results
indicate that there was a reduction in oxidative stress after
estrogen treatment. Our data are in agreement with Baeza et
al. [50], who also demonstrated that estrogen in a conven-
tional dose was able to decrease oxidative stress in liver, heart,
and kidney from ovariectomized rats.
This scenario, where antioxidants are increased and ROS
concentration is decreased, contributes to a more favorable
redox balance.
5. Conclusion
In conclusion, based on our results, estrogen therapy, even in
a low dose, reduced cardiac ROS concentration and increased
enzymatic and nonenzymatic antioxidants in ovariectomized
rats. This was reflected in improved left ventricle function
and cardiac autonomic control. Once these cardioprotective
effects were similar in low and high dose of estrogen, it is
reasonable to recommend low doses in clinical settings to
avoid undesirable side effects associated with the high dose.
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